Tatva Chintan Pharma Chem ‘s Q3 2024-25 Latest News: Profit Decreases by 95.95% YoY

Today, we’re looking at Tatva Chintan Pharma Chem Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 2.01 %. However, it did see a marginal increase of 2.88 % from the previous quarter. Expenses ticked up slightly by 1.18 % quarter-on-quarter, aligning with the annual rise of 7.68 %. Operating profit, while down -35.73 % compared to last year, faced a quarter-on-quarter increase of 26.7 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -4.83 %, but an expansion of 1.55 % sequentially. Other income fell by -88.33 % compared to the last quarter, despite an annual decline of -96.36 %. Interest expenses surged remarkably by 147.06 % from the previous quarter, yet the year-over-year increase remains at a moderate 10.53 %. Depreciation costs climbed by 1.62 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 5.17 %. Profit before tax declined annually by -104.38 % but saw an increase from the preceding quarter by 77.45 %.
Tax expenses as a percentage of profits decreased slightly by -192.84 % compared to last year, with a more notable quarter-on-quarter decrease of -123.75 %. Net profit fell by -95.95 % year-on-year but experienced a 121.21 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -95.95 % but a quarterly rise of 120.69 %. In summary, Tatva Chintan Pharma Chem Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Tatva Chintan Pharma Chem Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 2.01 % year-on-year growth, however, there was a minor increase of 2.88 % from the previous quarter. Expenses rose by 7.68 % compared to the previous year, with a 1.18 % increase quarter-on-quarter. Operating Profit dropped by -35.73 % annually, and saw a 26.7 % increase from the last quarter.
Net Profit showed yearly decrease of -95.95 %, and experienced a 121.21 % increase from the previous quarter. Earnings Per Share (EPS) fell by -95.95 % annually, however rose by 120.69 % compared to the last quarter. In essence, while Tatva Chintan Pharma Chem Limited faces strong annual decline indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.